Abstract
A tumour-positive proximal margin (PPM) after extended gastrectomy for oesophagogastric junction (OGJ) adenocarcinoma is observed in approximately 2–20% of patients. Although a PPM is an unfavourable prognostic factor, the clinical relevance remains unclear as it may reflect poor tumour biology. This narrative review analyses the most relevant literature on PPM after gastrectomy for OGJ cancers. Awareness of the risk factors and possible measures that can be taken to reduce the risk of PPM are important. In patients with a PPM, surgical and non-surgical treatments are available but the effectiveness remains unclear.
Keywords: Positive resection margin, R1, Extended total gastrectomy, Cardia cancer, Junctional adenocarcinoma
Introduction
The incidence of oesophagogastric junction (OGJ) adenocarcinoma has been gradually increasing both in Western and Asian countries [1, 2]. OGJ cancer involves subcardial, cardia and lower oesophageal adenocarcinomas. The Siewert classification is most often used to classify OGJ cancer. Three types are distinguished to facilitate interpretation of studies on OGJ cancer [3]. However, molecular subtyping of OGJ cancer has identified different subtypes which do not always correlate with the anatomical partition or patterns of nodal dissemination [4]. Hence, the optimal management of OGJ cancer remains uncertain [5].
Most surgeons would agree that the preferred surgical treatment for type I (lower oesophageal adenocarcinoma) is oesophagectomy with mediastinal lymph node dissection. For type III cancers (subcardial adenocarcinoma), total gastrectomy with partial oesophagectomy is performed [6]. For type II cancers (cardia cancer), both surgical approaches may be valid [7]. According to a survey extended to surgeons worldwide between 2013 and 2014, while Asian and South American centres seemed to perform extended total gastrectomy more often, European centres showed a more balanced proportion of the two approaches for Siewert II cancers [8]. Total gastrectomy facilitates a more complete abdominal (D2) lymphadenectomy, avoids postoperative morbidity related to a transthoracic approach and may result in less postoperative functional problems [9–11]. The downside of extended gastrectomy for type II cancer is the risk of an incomplete microscopic surgical resection (R1) at the proximal margin (oesophageal margin) [12]. On the other hand, oesophagectomy with gastric tube reconstruction via the transthoracic approach enables an extended two-field lymphadenectomy (abdominal and thoracic) and nearly eliminates the risk of a positive proximal margin. However, this approach is associated with a higher rate of respiratory complications and poorer functional outcomes [9, 10].
The main goal of any surgical treatment with curative intention is to achieve a complete resection of the tumour. However, the prevalence of a (microscopic) positive resection margin––proximal, distal or circumferential––after extended total gastrectomy for OGJ and gastric cancer ranges from 2.8 to 20% [13]. Here, in this narrative review, we discuss the risk factors, preventive strategies and (postoperative) treatments for positive proximal margin (PPM) after gastrectomy for OGJ cancer.
Causes
A PPM is often only diagnosed on definitive histopathological examination of the resection specimen. This is generally due to an underestimation of the proximal extension of the tumour intraoperatively by the surgeon, often within the submucosal layer. It is therefore important to have a rigorous preoperative assessment by endoscopy and endoscopic ultrasonography (EUS). Three endoscopically visible landmarks should be assessed: the Z-line, gastric folds and the diaphragmatic pinch. Submucosal extension of the tumour makes it particularly difficult to judge the degree of oesophageal involvement. In this instance, EUS can be helpful. Furthermore, a minimum length of macroscopic oesophageal safety margin should be respected during surgical resection [14], although most guidelines do not report specifically on the required margin for OGJ cancer (Table 1).
Table 1.
Guidelines on safe macroscopic resection margins for gastric and OGJ cancer
National guidelines | Indication |
---|---|
Japanese [15] |
3 cm is recommended for T2 or deeper tumours with an expansive growth pattern and 5 cm for those with an infiltrative growth pattern. For T1 tumours, a gross resection margin of 2 cm should be obtained For tumours invading the esophagus, resection margin > 5 cm is not necessarily required, but frozen section examination of the resection line is preferable to ensure an R0 resection |
ESMO-ESSO-ESTRO [16] |
5 cm, if diffuse type 8 cm *Unspecific for OGJ cancer |
NCCN [17] |
4 cm or greater for T1b/T3. T4 tumours require en bloc resection of involved structures *Unspecific for OGJ cancer |
AUGIS [18] |
An ex vivo proximal margin of > 3.8 cm of normal oesophagus (which equates to 5 cm in vivo) The role of intraoperative histological examination of the proximal resection margin is mandatory in this situation |
Dutch [19] |
Proximal and distal margin of 6 cm intraoperatively When the distance to the proximal margin is less than 6 cm and a more extended resection would be possible if a frozen section would result positive, the use of frozen section analysis is recommended |
German [20] |
5 cm if intestinal Lauren’s pattern, 8 cm if diffuse type *Unspecific for OGJ cancer |
French [21] |
If R0 margins achievable, no distance required *Unspecific for OGJ cancer |
Italian [22] |
At least 3 cm is recommended for T2 or deeper tumours with an expansive growth pattern, and 5 cm is recommended for those with infiltrative growth pattern and diffuse Lauren histotype. For T1 tumours, margin of 2 cm For tumours invading the esophagus, a 5 cm margin is not necessarily required, but frozen section examination of the resection line is desirable to ensure an R0 resection |
In some patients, the possibility of a PPM is accepted by the surgeon during the operation. For example, if the patient is considered too frail to undergo a more extensive resection. However, one should always consider the need to change the surgical approach and take this into account when selecting patients for total gastrectomy for OGJ cancer.
Distal gastrectomy may treat cancer-related symptoms (e.g., gastric outlet obstruction, bleeding) that are difficult to palliate with other modalities. In selected patients, this approach improves quality of life even when an incomplete tumour resection has been performed [23]. Total gastrectomy is associated with greater morbidity. Hence, many judge palliative total gastrectomy as too aggressive, also given the findings from the REGATTA trial that surgery does not prolong survival compared to chemotherapy alone [6, 24].
Risk factors
Knowledge of the risk factors associated with a PPM could help increase the awareness of the surgical team leading to adaptation of surgical strategy or intraoperative assessment of the resection margin. The most frequently reported risk factors for a positive resection margin are shown in (Table 2). Large diameter of the tumour, advanced T classification, diffuse/mixed Lauren subtype and tumour location at the OGJ all increase the risk of a positive resection margin. In addition, Bissolati et al. found that a small macroscopic surgical margin of less than 2 cm for T1 and less than 3 cm for T2–T4 intestinal type tumours was an independent risk factor for a positive resection margin. This concurs with the recommendations of the Japanese guideline on gastrectomy for cancer [14, 15]. Van der Werf et al. also described a hospital volume of less than 20 gastrectomies per year as an independent risk factor. The benefit in high volume centres is likely to be multi-factorial encompassing staging accuracy, decision making and surgical experience [28].
Table 2.
Risk factors for a positive resection margin in gastric and OGJ cancer
References | Tumour size | cT | OGJ location | Diffuse/mixed pattern | Signet ring cell | Grading | pT | pN |
---|---|---|---|---|---|---|---|---|
Cho et al. [13] | – | – | Yes | – | Yes | G3-G4 | pT3-T4 | pN1-N3 |
Lee et al. [25] | > 5 cm | – | Yes | – | Yes | – | – | – |
Kim et al. [26] | – | – | Yes | Yes | – | – | – | – |
Squires et al. [27] | > 6.9 cm | – | Yes | – | Yes | – | – | – |
Bissolati et al. [14] | > 4 cm in T2-T4 diffuse/mixed pattern | – | Yes | Yes | Yes | – | pT3-T4 | – |
Van der Werf et al. [28] | – | cT3-T4 | Yes | Yes | – | – | – | pN + |
Kumazu et al. [29] | ≥ 8 cm | – | Yes | Yes | – | – | pT4 | – |
Does a positive proximal margin matter?
A systematic review and meta-analysis including 19,992 patients found an association of R1 status (circumferential, proximal or distal margin) with poorer overall survival (OS). A positive resection margin was also an independent prognostic factor irrespective of tumour stage [30]. Muneoka et al. analysed 2121 patients and reported a significantly worse 5 year OS and relapse-free survival (RFS) in patients with a positive resection margin in pT2-4 tumours, even when a re-resection was performed to obtain a definite R0 [31]. A worse 5 year recurrence-free survival (RFS) was not observed in patients with pT1 tumours, and only in these early tumours additive surgical resection was of benefit. This study and others [32, 33] found that a positive resection margin is associated with more advanced and aggressive tumours, which may explain the worse 5 year RFS. It would also explain why the recurrence pattern in patients with a positive resection margin is more frequently distant and not locoregional [31, 34]. Hence, worse OS and RFS in PPM cases would be related to an already advanced and aggressive disease, which relapses at distant sites earlier than from residual tumour at the resection margin. According to this theory, resection margin status would only impact on survival in early stage cancers, in which further treatments like re-resection may be of benefit.
How to prevent a positive proximal margin?
Accurate preoperative assessment of the tumour is crucial to limit the chance of an incomplete resection. Endoscopy and computed tomography (CT), often combined with EUS, are mandatory for assessment of T status and the extent of infiltration into the oesophagus. Tumour-positive regional lymph nodes in the mediastinum may also guide the surgeon in defining the surgical approach and as a result the oesophageal resection margin [35]. The value of PET/CT scan for clinical staging of OGJ cancer is not clear but may be used to exclude distant metastases and to evaluate response after neoadjuvant therapy [36]. One of the issues is that signet ring cancers tend to be less FDG avid and so the sensitivity for PET in these high risk tumours (even for longitudinal extension) may be reduced [37].
Data about the biological nature of the tumour in addition to tumour location may be helpful, although there are no clear guidelines yet. Poorly differentiated tumours and the presence of signet ring cells should raise the suspicion of submucosal extension. Neoadjuvant therapy is indicated for locally advanced tumours. Both chemotherapy (FLOT) [38] and chemoradiotherapy (CROSS) [39] have shown improvements in locoregional control and a reduction of positive resection margin rates in OGJ cancers. Hence, neoadjuvant treatment may prevent a PPM in cardia cancer courtesy of tumour down-staging. However, surgical decision making with regard to longitudinal margins should still be guided by initial staging rather than relying on a down-staging effect. This would mandate an accurate assessment of tumour extent at the time of diagnosis.
There is no consensus about the length of macroscopic appearing normal oesophagus that should be resected [40]. Some studies suggested minimum of 2 cm [14, 41]. However, it can be challenging to resect more oesophagus via the abdomen and still leave room for a safe oesophagojejunostomy. Extension of the resection to a partial oesophagectomy or oesophagogastrectomy via a transthoracic approach (right thoracoscopy/thoracotomy or left thoracophrenolaparotomy––Sweet approach) might be needed. For such extended resections, the surgical team must have expertise.
Intraoperatively, manual palpation is helpful in open surgery but is not possible during minimally invasive procedures. Hence, the threshold for conversion (or alternative solutions) should be low if the complete resection cannot be assured by laparoscopy. Intraoperative endoscopy may help assess the proximal margin of the tumour. This could be used in minimally invasive and open approaches. Kawakatsu et al. described the systematic combination of preoperative placement of marking clips and intraoperative endoscopy to determine the surgical margin in patients who undergo laparoscopic extended gastrectomy. They achieved a success rate of 98.9% negative margins during the initial transection [42].
Intraoperative evaluation of the proximal resection margin by performing a frozen section analysis may be the best technique to assess margin status. The accuracy lies between 93 and 99% [27, 43, 44]. False negative results do occur especially in patients with submucosal spread of the tumour, poor differentiation (diffuse or mixed tumours), preoperative neoadjuvant therapy or surgical trauma due to the stapler device. However, intraoperative frozen section analysis is a time and resource-consuming technique, and a pathologist needs to be available in real time. According to current evidence [14, 36], frozen section analysis should be used selectively in patients where the risk of infiltrated margins is high and there is the opportunity to re-resect the oesophagus. This recommendation is in line with Japanese, Italian and AUGIS gastric cancer guidelines [15, 18, 22], in which frozen section examination is considered preferable to ensure an R0 resection in OGJ cancer. Risk factors (Table 2) could help decide in which patients frozen section analysis should be performed. Kumazu et al. defined 6 risk factors for a positive resection margin: remnant gastric cancer, oesophageal invasion, tumour size, undifferentiated type, macroscopic type 4 and pT4 disease. They observed a positive resection margin in 21.3% of their patients when four risk factors were present and 85.7% when five factors were identified. This led to their recommendation to perform a frozen section analysis in patients with four or more risk factors [29].
How to manage a positive proximal margin?
When a positive proximal margin is diagnosed intraoperatively (e.g., by frozen section analysis), re-resection should follow. This may entail the need for changing the surgical approach as discussed earlier. When the proximal margin is positive at histopathological examination of the resection specimen after the operation, further treatments should be considered and tailored to tumour and patient characteristics. There is controversy regarding the benefit of performing a re-resection by a second operation. Some studies have described a lower incidence of local relapse after re-resection, but similar poor survival compared to patients that did not undergo a re-resection [27, 31]. According to Morgagni et al. a positive resection margin reflects advanced disease: regional and distant metastases are influenced by margin status and haematogenous and peritoneal metastatic relapse occurred earlier than local recurrence in patients with a positive resection margin [40]. Hence, some recommend re-resection when feasible and only for patients with N0 status or limited nodal involvement (less than 3–5 positive nodes) [13, 40, 45–47]. Furthermore, Bickenbach et al. suggested that only tumours with a limited depth of infiltration (≤ pT1–T2) may gain a survival benefit by re-resection [48].
Multimodal treatment with adjuvant chemoradiotherapy (CRT) has also been proposed as alternative to surgery. Stiekema et al. showed in a Dutch retrospective cohort study including 409 patients with a R1 resection (proximal, distal or circumferential) that adjuvant CRT was associated with improved survival when compared to patients without adjuvant CRT treatment [49]. In another study, the same authors analysed recurrence-free survival in gastric cancer patients treated with CRT after surgery concluding that an R1 resection was not an adverse prognostic factor [50]. A limitation of both studies was the low lymph node yield in most patients (< 15 nodes) and the heterogeneous population included. The survival benefit in the adjuvant CRT group could be due to better locoregional control in patients without an adequate (D2) lymphadenectomy. In addition, the finding that R1 status was not associated with RFS indicates that other more important factors dictate prognosis. Dikken et al. found that postoperative CRT had a major impact on local recurrence in resectable gastric cancer when a D1 lymphadenectomy was performed [51]. On the contrary, in patients with a D2 lymph node resection, adjuvant CRT did not shown any difference in local recurrence when compared to patients treated with surgery alone. Moreover, Ma et al. found that most patients with positive resection margin had advanced pathologic stage and that adjuvant treatment (28% CRT, 20% chemotherapy alone, 3% radiation alone, 1% reoperation) did not improve RFS or OS. The main failure pattern they found was distant recurrence (72%), suggesting that if patients are considered for adjuvant radiotherapy, they should be carefully selected [34]. Zhou et al. concluded that adjuvant CRT improves locoregional control and that nodal status may be the most important predictor for patient selection: only patients with pN0-2 disease may benefit from additional radiotherapy after R1 resection [52].
Conclusion
Total gastrectomy for cancer aims to completely remove the primary tumour including locoregional lymph nodes. This is defined as achieving negative resection margins and a D2 nodal dissection. The best surgical strategy can only be planned after a comprehensive preoperative assessment of the patient (frailty, comorbidities, patient’s wishes) and location, stage and biological behaviour of the tumour. The surgeon should be involved in every step of this process. Awareness of risk factors for a positive resection margin could help in clinical decision making but unexpected intraoperative findings may lead to adaptation of the surgical management. When a positive resection margin is involved, further treatments options, such as re-resection and/or (chemo) radiation, should be carefully considered in selected cases.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data availability
All data generated or analysed during this study are included in this published article.
Declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Han WH, Eom BW, Yoon HM, Reim D, Kim YW, Kim MS, et al. The optimal extent of lymph node dissection in gastroesophageal junctional cancer: retrospective case control study. BMC Cancer. 2019;19:719. doi: 10.1186/s12885-019-5922-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Bartel M, Brahmbhatt B, Bhurwal A. Incidence of gastroesophageal junction cancer continues to rise: analysis of surveillance, epidemiology, and end results (SEER) database. J Clin Oncol. 2019;37(4 suppl):40–40. doi: 10.1200/JCO.2019.37.4_suppl.40. [DOI] [Google Scholar]
- 3.Rüdiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232(3):353–361. doi: 10.1097/00000658-200009000-00007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Suh YS, Na D, Lee JS, et al. Comprehensive molecular characterization of adenocarcinoma of the gastroesophageal junction between esophageal and gastric adenocarcinomas. Ann Surg. 2020 doi: 10.1097/SLA.0000000000004303. [DOI] [PubMed] [Google Scholar]
- 5.Lin D, Khan U, Goetze TO, Reizine N, Goodman KA, Shah MA, et al. Gastroesophageal junction adenocarcinoma: is there an optimal management? Am Soc Clin Oncol Educ Book. 2019;39:e88–e95. doi: 10.1200/EDBK_236827. [DOI] [PubMed] [Google Scholar]
- 6.Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol. 2011;12(3):296–305. doi: 10.1016/S1470-2045(10)70125-X. [DOI] [PubMed] [Google Scholar]
- 7.Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, et al. First St Gallen EORTC gastrointestinal cancer conference 2012 expert panel. Highlights of the EORTC St. Gallen international expert consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012;48(16):2941–53. doi: 10.1016/j.ejca.2012.07.029. [DOI] [PubMed] [Google Scholar]
- 8.Haverkamp L, Seesing MF, Ruurda JP, Boone J, Hillegersberg VR. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer. Dis Esophagus. 2017;30(1):1–7. doi: 10.1111/dote.12480. [DOI] [PubMed] [Google Scholar]
- 9.Haverkamp L, Ruurda JP, van Leeuwen MS, Siersema PD, van Hillegersberg R. Systematic review of the surgical strategies of adenocarcinomas of the gastroesophageal junction. Surg Oncol. 2014;23(4):222–228. doi: 10.1016/j.suronc.2014.10.004. [DOI] [PubMed] [Google Scholar]
- 10.Fuchs H, Hölscher AH, Leers J, Bludau M, Brinkmann S, Schröder W, et al. Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy? Gastric Cancer. 2016;19(1):312–317. doi: 10.1007/s10120-015-0466-3. [DOI] [PubMed] [Google Scholar]
- 11.Brown AM, Giugliano DN, Berger AC, Pucci MJ, Palazzo F. Surgical approaches to adenocarcinoma of the gastroesophageal junction: the Siewert II conundrum. Langenbecks Arch Surg. 2017;402(8):1153–1158. doi: 10.1007/s00423-017-1610-9. [DOI] [PubMed] [Google Scholar]
- 12.Imamura Y, Watanabe M, Oki E, Morita M, Baba H. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg. 2020;5(1):46–59. doi: 10.1002/ags3.12406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Cho BC, Jeung HC, Choi HJ, Rha SY, Hyung WJ, Cheong JH, et al. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute. J Surg Oncol. 2007;95(6):461–468. doi: 10.1002/jso.20731. [DOI] [PubMed] [Google Scholar]
- 14.Bissolati M, Desio M, Rosa F, Rausei S, Marrelli D, Baiocchi GL, et al. Risk factor analysis for involvement of resection margins in gastric and esophagogastric junction cancer: an Italian multicenter study. Gastric Cancer. 2017;20(1):70–82. doi: 10.1007/s10120-015-0589-6. [DOI] [PubMed] [Google Scholar]
- 15.Japanese Gastric Cancer Association Japanese gastric cancer treatment guidelines 2018 (5th edition) Gastric Cancer. 2021;24(1):1–21. doi: 10.1007/s10120-020-01042-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014;40(5):584–591. doi: 10.1016/j.ejso.2013.09.020. [DOI] [PubMed] [Google Scholar]
- 17.Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D’Amico TA, Das P, et al. NCCN gastric cancer panel. Gastric Cancer J Natl Compr Canc Netw. 2010;8(4):378–409. doi: 10.6004/jnccn.2010.0030. [DOI] [PubMed] [Google Scholar]
- 18.Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Association of upper gastrointestinal surgeons of great britain and Ireland, the British society of gastroenterology and the British association of surgical oncology. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60(11):1449–72. doi: 10.1136/gut.2010.228254. [DOI] [PubMed] [Google Scholar]
- 19.Landelijke werkgroep Gastro-intestinale Tumoren. Richtlijn: Maagcarcinoom (2.2) - richtlijnendatabase. 2017 [cited 2022 Jan 24]. Available from: https://richtlijnendatabase.nl/gerelateerde_documenten/f/16316/IKNL%20richtlijn%20Maagcarcinoom.pdf
- 20.Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, et al. AWMF; AWMF S3-Leitlinie "Magenkarzinom" - Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs (AWMF-Regist-Nr 032–009-OL) [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"] Z Gastroenterol. 2011;49(4):461–531. doi: 10.1055/s-0031-1273201. [DOI] [PubMed] [Google Scholar]
- 21.Haute Autorité de Santé (HAS) and Institut National du Cancer (2011) Guide—Affection de longue durée (ALD). Tumeur maligne, affection maligne du tissue lymphatique ou hématopoiétique. Cancer de l’estomac. http://www.has-sante.fr, http://www.e-cancer.fr. Accessed date 24 Jan 2022
- 22.De Manzoni G, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M, et al. The Italian research group for gastric cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer. 2017;20(1):20–30. doi: 10.1007/s10120-016-0615-3. [DOI] [PubMed] [Google Scholar]
- 23.Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ. Dutch gastric cancer group. Value of palliative resection in gastric cancer. Br J Surg. 2022;89(11):1438–43. doi: 10.1046/j.1365-2168.2002.02220.x. [DOI] [PubMed] [Google Scholar]
- 24.Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–318. doi: 10.1016/S1470-2045(15)00553-7. [DOI] [PubMed] [Google Scholar]
- 25.Lee JH, Ahn SH, Park Do J, Kim HH, Lee HJ, Yang HK. Clinical impact of tumor infiltration at the transected surgical margin during gastric cancer surgery. J Surg Oncol. 2012;106:772–776. doi: 10.1002/jso.23123. [DOI] [PubMed] [Google Scholar]
- 26.Kim SY, Hwang YS, Sohn TS, Oh SJ, Choi MG, Noh JH, et al. The predictors and clinical impact of positive resection margins on frozen section in gastric cancer surgery. J Gastric Cancer. 2012;12:113–119. doi: 10.5230/jgc.2012.12.2.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Squires MH, 3rd, Kooby DA, Pawlik TM, Weber SM, Poultsides G, Schmidt C, et al. Utility of the proximal margin frozen section for resection of gastric adenocarcinoma: a 7-institution study of the US gastric cancer collaborative. Ann Surg Oncol. 2014;21(13):4202–4210. doi: 10.1245/s10434-014-3834-z. [DOI] [PubMed] [Google Scholar]
- 28.van der Werf LR, Cords C, Arntz I, Belt EJT, Cherepanin IM, Coene PLO, et al. Population-based study on risk factors for tumor-positive resection margins in patients with gastric cancer. Ann Surg Oncol. 2019;26(7):2222–2233. doi: 10.1245/s10434-019-07381-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Kumazu Y, Hayashi T, Yoshikawa T, Yamada T, Hara K, Shimoda Y, et al. Risk factors analysis and stratification for microscopically positive resection margin in gastric cancer patients. BMC Surg. 2020;20(1):95. doi: 10.1186/s12893-020-00744-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Jiang Z, Liu C, Cai Z, Shen C, Yin Y, Yin X, et al. Impact of surgical margin status on survival in gastric cancer: a systematic review and meta-analysis. Cancer Control. 2021 doi: 10.1177/10732748211043665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Muneoka Y, Ohashi M, Ishizuka N, Hayami M, Makuuchi R, Ida S, et al. Risk factors and oncological impact of positive resection margins in gastrectomy for cancer: are they salvaged by an additional resection? Gastric Cancer. 2021 doi: 10.1007/s10120-021-01238-w. [DOI] [PubMed] [Google Scholar]
- 32.Stiekema J, Cats A, Kuijpers A, van Coevorden F, Boot H, Jansen EP, et al. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? Eur J Surg Oncol. 2013;39(7):686–93. doi: 10.1016/j.ejso.2013.02.026. [DOI] [PubMed] [Google Scholar]
- 33.Blackham AU, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, et al. Is linitis plastica a contraindication for surgical resection: a multi-institution study of the U.S. gastric cancer collaborative. Ann Surg Oncol. 2016;23(4):1203–11. doi: 10.1245/s10434-015-4947-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Ma LX, Espin-Garcia O, Lim CH, Jiang DM, Sim HW, Natori A, et al. Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers. J Gastrointest Oncol. 2020;11(2):356–365. doi: 10.21037/jgo.2020.03.03. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev. 2015 doi: 10.1002/14651858.CD009944.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Fuster D, Mayoral M, Rubello D, Pineda E, Fernández-Esparrach G, Pagès M, et al. Is there a role for PET/CT with esophagogastric junction adenocarcinoma? Clin Nucl Med. 2015;40(3):e201–e207. doi: 10.1097/RLU.0000000000000661. [DOI] [PubMed] [Google Scholar]
- 37.Park K, Jang G, Baek S, Song H. Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer. Tumori. 2014;100(2):201–6. doi: 10.1700/1491.16415. [DOI] [PubMed] [Google Scholar]
- 38.Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957. doi: 10.1016/S0140-6736(18)32557-1. [DOI] [PubMed] [Google Scholar]
- 39.Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–1098. doi: 10.1016/S1470-2045(15)00040-6. [DOI] [PubMed] [Google Scholar]
- 40.Morgagni P, La Barba G, Colciago E, Vittimberga G, Ercolani G. Resection line involvement after gastric cancer treatment: handle with care. Updates Surg. 2018;70(2):213–223. doi: 10.1007/s13304-018-0552-2. [DOI] [PubMed] [Google Scholar]
- 41.Yuan P, Yan Y, Jia Y, Wang J, Li Z, Wu Q. Intraoperative gastroscopy to determine proximal resection margin during totally laparoscopic gastrectomy for patients with upper third gastric cancer. J Gastrointest Oncol. 2021;12(1):142–152. doi: 10.21037/jgo-20-277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Kawakatsu S, Ohashi M, Hiki N, Nunobe S, Nagino M, Sano T. Use of endoscopy to determine the resection margin during laparoscopic gastrectomy for cancer. Br J Surg. 2017;104(13):1829–1836. doi: 10.1002/bjs.10618. [DOI] [PubMed] [Google Scholar]
- 43.Spicer J, Benay C, Lee L, Rousseau M, Andalib A, Kushner Y, et al. Diagnostic accuracy and utility of intraoperative microscopic margin analysis of gastric and esophageal adenocarcinoma. Ann Surg Oncol. 2014;21(8):2580–2586. doi: 10.1245/s10434-014-3669-7. [DOI] [PubMed] [Google Scholar]
- 44.Berlth F, Kim WH, Choi JH, Park SH, Kong SH, Lee HJ, et al. Prognostic impact of frozen section investigation and extent of proximal safety margin in gastric cancer resection. Ann Surg. 2020;272(5):871–878. doi: 10.1097/SLA.0000000000004266. [DOI] [PubMed] [Google Scholar]
- 45.Cascinu S, Giordani P, Catalano V, Agostinelli R, Catalano G. Resection-line involvement in gastric cancer patients undergoing curative resections: implications for clinical management. Jpn J Clin Oncol. 1999;29(6):291–293. doi: 10.1093/jjco/29.6.291. [DOI] [PubMed] [Google Scholar]
- 46.Kim SH, Karpeh MS, Klimstra DS, Leung D, Brennan MF. Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg. 1999;3(1):24–33. doi: 10.1016/s1091-255x(99)80004-3. [DOI] [PubMed] [Google Scholar]
- 47.Aurello P, Magistri P, Nigri G, Petrucciani N, Novi L, Antolino L, et al. Surgical management of microscopic positive resection margin after gastrectomy for gastric cancer: a systematic review of gastric R1 management. Anticancer Res. 2014;34(11):6283–6288. [PubMed] [Google Scholar]
- 48.Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol. 2013;20(8):2663–2668. doi: 10.1245/s10434-013-2950-5. [DOI] [PubMed] [Google Scholar]
- 49.Stiekema J, Trip AK, Jansen EP, Aarts MJ, Boot H, Cats A, et al. Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study. Ann Surg Oncol. 2015;22(2):581–588. doi: 10.1245/s10434-014-4032-8. [DOI] [PubMed] [Google Scholar]
- 50.Stiekema J, Trip AK, Jansen EP, Boot H, Cats A, Ponz OB, et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol. 2014;21(4):1107–1114. doi: 10.1245/s10434-013-3397-4. [DOI] [PubMed] [Google Scholar]
- 51.Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28(14):2430–2436. doi: 10.1200/JCO.2009.26.9654. [DOI] [PubMed] [Google Scholar]
- 52.Zhou ML, Li GC, Yang W, Deng WJ, Hu R, Wang Y, et al. Adjuvant chemoradiotherapy versus adjuvant chemotherapy for R1 resected gastric cancer: a retrospective cohort study. Br J Radiol. 2018;91(1089):20180276. doi: 10.1259/bjr.20180276. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated or analysed during this study are included in this published article.